Latest Headlines

Latest Headlines

GSK overhauls patent policies for low-income countries to spur generics

GlaxoSmithKline plans a radical shift in patent policy that seeks to encourage copies of its medicines in poor countries, widening access and possibly diminishing calls for compulsory licenses or other challenges based on price.

Former GSK staffers launch new Canadian CRO

A new contract research organization has risen out of the flames of Glaxo's former Canadian vaccines unit as it sets up shop in the pharma company's old Laval facility.

GSK planning combo vax launches in India, report says

Through its recent purchases and divestitures, GlaxoSmithKline has placed an increased emphasis on its vaccines business worldwide. Now, it'll look to build its vaccine offerings in one of the world's most populous countries, with an executive this week saying the British pharma giant aims to launch in India multiple combination vaccines in the coming months.

GSK chief Witty may be leaving, but he hopes his strategy sticks around

GlaxoSmithKline CEO Andrew Witty may be heading for the door next year--but he's still touting the strategy he put in place there, and he believes it won't be following him out.

Letter to the Editor: Tufts' Joseph A. DiMasi debunks the Andrew Witty R&D; cost meme

In particular, I would like to correct what I believe is a misinterpretation of something that GSK CEO Andrew Witty stated at a healthcare conference in 2013.

GSK partnering with Germany's Miltenyi Biotec on cell and gene therapy R&D;

GlaxoSmithKline is collaborating with Germany's Miltenyi Biotec on the "industrialization" of cell and gene therapy, as part of the Big Pharma's effort to harness the technique for the development of therapies to treat cancer and rare diseases.

GlaxoSmithKline CEO packs his bags for March 2017 exit

It's official: GlaxoSmithKline CEO Andrew Witty is moving on. At the helm of the U.K.-based drugmaker since 2008, Witty will step down in March 2017, clearing the way for a new captain to chart a new course.

GSK adds Miltenyi Biotec to its oncology shopping CAR-T as Witty checks out

GlaxoSmithKline and Miltenyi Biotec have signed an R&D; cell and gene therapy pact that will see the British Big Pharma delve deeper into the brave new world of CAR-T-based oncology treatments. This brave new world will not however feature its leader, Andrew Witty, who announced his retirement today.

GlaxoSmithKline's nicotine franchise pairs up with smoking cessation app

In a twist on the traditional smoking cessation model, GlaxoSmithKline is pairing with 2morrow's SmartQuit app to supply patches to smokers who have already completed the app plan.

Adherium wins approval to sell its 'smart' inhaler devices in Canada

Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders.